Article Details
Retrieved on: 2021-06-15 07:18:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
In a phase II clinical trial, the drug candidate AADvac1, developed by biotech company Axon Neuroscience, was shown to be safely tolerated by ...
Article found on: www.sciencealert.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here